Macular Degeneration Foundation

ARVO 2024: Emily Y. Chew M.D.

AREDS Vitamin Formula Study Results After 10 years Emily Y. Chew, M.D. NIH Distinguished Investigator DECA Clinical Trials Branch National Eye Institute 10 Center Drive, Bethesda, MD-20892 301-496-6583 https://irp.nih.gov/

ARVO 2024: Dun Jack Fu PhD

A deep-learning approach to identifying quantitative OCT biomarkers predictive of visual deficit measured by microperimetry at 24 months in OAKS trial Dun Jack “DJ” Fu, BM BCh, PhD Moorfields Eye HospitalUniversity College London Kings College London Phone: +44 20 7253 3411https://profiles.ucl.ac.uk/91906-dun-…https://www.moorfields.nhs.uk/

ARVO 2024: Richard B. Thompson, PhD

Richard B. Thompson, PhDUniversity of Maryland School of Medicine Dr. Imre LengyelQueen’s University Belfast Bruch’s Membrane Calcification in Pseudoxanthoma Elasticum: Comparing Histopathology and Clinical Imaging

ARVO 2024: Margaret DeAngelis, Ph.D

Margaret DeAngelis, M.S., Ph.DEndowed Chair ProfessorDepartment of OphthalmologyJacobs School of Medicine & Biomedical Scienceshttps://medicine.buffalo.edu/ Genomic and molecular underpinnings of AMD

ARVO 2024: Samuel Barone, MD

Samuel Barone, MDChief Medical OfficerNanoscope Therapeutics, Inc.Trinity Towers2777 N. Stemmons Fwy.Dallas, TX 75207(817) 857-1186 Positive Top-line Results fromRandomized Controlled Trials of MCO-010Gene Therapy for RP and Stargardt

ARVO 2024: Samuel Barone, MD

Samuel Barone, MDChief Medical OfficerNanoscope Therapeutics, Inc.Trinity Towers2777 N. Stemmons Fwy.Dallas, TX 75207(817) 857-1186 MCO-020 Gene Therapy for Macular Degeneration and GA

ARVO 2024: Charles Zhang MD

Charles Zhang, M.D.SUNY BuffaloJacob’s School of Medicine & Biomedical Sciences Genome-wide Pleiotropy Analysis of AMD andLate-Onset Alzheimer’s Disease Reveals SharedGenetic Architecture in the Complement Pathway

ARVO 2024: Ruchi Sharma Ph.D.

Ruchi Sharma Ph.D.Stem Cell Transplants for Dry AMD To find out about clinical studies at NEIand other NIH institutes, visit the NIH Clinical Centerhttp://www.nei.nih.gov or call 1-800-411-1222.

ARVO 2024: Karen Allison, MD

Karen Allison, MDPresentation: Genetic link of eye diseases in multi-generational African Families

ARVO 2024: Karen Allison, MD

Karen Allison, MD Presentation: Utilization of Eye Care in Western New York – A Guidance to Improve Healthcare challenges in underserved communities

ARVO 2024: Ashkan M. Abbey, MD

Ashkan M. Abbey, MD, FASRS, FAAO Presentation: Long-term efficacy and safety of pegcetacoplan over 36 months including 12-month results of the GALE open-label extension study

ARVO 2024: Roland Mattern

Roland Mattern, Director of Sales – eSight Presentation: eSight Go by Gentex New Version of Vision Enhancing Wearable Assistive Technology Device

ARVO 2024: Clark Tedford, PhD

Clark Tedford, PhDPresentation: LumiThera – Photobiomodulation light therapy for dry amd

ARVO 2024: Treefa Shwani

Treefa Shwani, PhD student Presentation: Decoding Genome-wide miRNA Signatures in Human Donor Eye Tissue Across Early and Late Stages of Dry AMD

AAO 2023: Christine Kay MD

Christine Kay, MDVitreo Retinal Associates, Gainsville FL4340 Newberry Rd #202Gainesville, FL 32607(352) 371-2800 http://www.vra-pa.com Presentation: PA025 ALK-001 (C20-D3-Vitamin A) Slows the Growth of Atrophic Lesions in ABCA4-Related Stargardt Disease:Results of a Randomized, Placebo-Controlled Clinical Trial, the TEASE Study

Harvard 2023: Bharti & Sharm

Kapil Bharti, Ph.D. Presentation: New Stem Cell Treatment Developed for AMD Ruchi Sharma, Ph.D. Presentation: Triphasic developmentally guided protocol to generate retinal pigment epithelium from induced pluripotent stem cells NEI Ocular and Stem Cell Translational Unit National Eye Institute, NIH http://www.nei.nih.gov Study Contact: Name: Angel H Garced, R.N. Phone Number: …

ARVO 2023: Samarendra Mohanty PhD

Samarendra Mohanty, Ph. DPresident and Founder Nanoscope Technologieshttps://nanostherapeutics.com(817) 857-1186 Presentation: Using multi characteristic opsin with capsid freeplasmid with laser targeted delivery to repairatrophy in advanced dry AMD

ARVO 2023: Bhattacharya & Mohanty

Sulagna Bhattacharya, Co-Founder & CEOSamarendra Mohanty, Co-Founder & President Nanoscope TherapeuticsTrinity Towers2777 N. Stemmons Fwy. Dallas, TX 75207(817) 857-1186 Presentation: Gene therapy delivers light sensitive Multi-Characteristic Opsins (MCOs) into retinal cells with potential to detect ambient light to treat retinal diseases

ARVO 2023: Demetrios Vavvas MD PhD

Demetrios Vavvas MD PhD Solman and Libe Friedman Professor of OphthalmologyHarvard Medical SchoolMass Eye and Eareye.hms.harvard.edu Presentation: Concerns with SYFOVRE® (pegcetacoplan injection) clinical trial data and under reported adverse side effects

ARVO 2023: Dimitra Skondra MD PhD

Dimitra Skondra MD PhD Presentation: Possible protective properties of Metformin may be beneficial for Macular Degeneration Patients. The link between gut health and over use of broad spectrum antibiotics to Macular Degeneration. Possible eye drop treatment for macular hole.

ARVO 2023: Karen Allison MD

Karen Allison MD Presentation: Glaucoma, AMD and Vascular Diseases, and the Diversification needed in studies and Clinical Trials

ARVO 2023: Charles Zhang MD

Charles Zhang, MD Presentation: Axonal guidance signaling pathway confer protection against progression to neovascular disease AMD

ARVO 2023: Timothy Corson, PhD

Tim Corson PhD Presentation: Sustained Release Griseofulvin / Targeting Ref-1 protein with APX3330 drug as new treatments for AMD

AAO 2022: Divya Parthasarathy Rao MD

Divya Parthasarathy Rao MD Presentation: Deep-learning automated screening tool for AMD Remidio Innovative Solutions Inchttp://www.remidio.com

AAO 2022: Yannis Paulus MD

Presentation: Clinical Validation of a Handheld Device forRemote Monitoring of Dry Macular Degeneration Yannis Paulus MD University of Michigan, Kellogg Eye Centerypaulus@med.umich.eduYannis Paulus Labhttp://www.paulus.lab.medicine.umich.edu734-764-4182